Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Seroprevalence of anti-SARS-CoV-2 in patients with hepatitis B and C: a pre-vaccination study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Editora Country of Publication: Brazil NLM ID: 9812937 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1678-4391 (Electronic) Linking ISSN: 14138670 NLM ISO Abbreviation: Braz J Infect Dis Subsets: MEDLINE
    • Publication Information:
      Publication: 2010- : Rio de Janeiro : Elsevier Editora
      Original Publication: Salvador, Bahia, Brazil : Contexto, c1997-
    • Subject Terms:
      COVID-19*/epidemiology ; COVID-19*/immunology ; COVID-19*/prevention & control ; Hepatitis B*/epidemiology ; Hepatitis B*/prevention & control ; Hepatitis B*/immunology ; SARS-CoV-2*/immunology ; Hepatitis C*/epidemiology ; Antibodies, Viral*/blood; Humans ; Seroepidemiologic Studies ; Female ; Male ; Adult ; Middle Aged ; Brazil/epidemiology ; Young Adult ; Aged ; Immunoglobulin G/blood ; Immunoglobulin M/blood ; Adolescent
    • Abstract:
      The serological markers for the diagnosis of COVID-19 plays an important role in the epidemiological investigation of the pandemic. This study aims to assess the prevalence of anti-SARS-CoV-2 in hepatitis B and C patients in a pre-vaccination of COVID-19 period. Between March 2020 and January 2021, 199 serum samples from individuals with HBsAg/HBV DNA or anti-HCV/HCV RNA positivity were tested for antibodies (IgM and IgG) against SARS-CoV-2 using Electrochemiluminescent Immunoassay (ECLIA). Among these, 50.3 % (100/199) tested positive for hepatitis C virus infection and 49.7 % (99/199) for hepatitis B virus, confirmed through molecular and serological diagnosis. The anti-SARS-CoV-2 seroprevalence was 24.1 % (48/199) in this population, with 23.23 % (23/99) hepatitis B and 25 % (25/100) hepatitis C patients tested positive for anti-SARS-CoV-2. The higher seroprevalence of anti-SARS-CoV-2 (16.58 %, 33/199) was detected among those over-40 years of age and the month of November 2020 had the highest number of detections 9 % (18/199) with the majority living in impoverished and neglected neighborhoods in the city of Rio de Janeiro. We found a high prevalence of anti-SARS-CoV-2 in patients with viral hepatitis before COVID-19 vaccination. This demonstrates the high exposure of this population during the period of social isolation.
      Competing Interests: Conflicts of interest The authors declare no conflicts of interest.
      (Copyright © 2024 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.)
    • Contributed Indexing:
      Keywords: Antibodies; COVID-19; Hepatitis; Seroprevalence
    • Accession Number:
      0 (Antibodies, Viral)
      0 (Immunoglobulin G)
      0 (Immunoglobulin M)
    • Publication Date:
      Date Created: 20240426 Date Completed: 20240617 Latest Revision: 20240617
    • Publication Date:
      20240619
    • Accession Number:
      PMC11096827
    • Accession Number:
      10.1016/j.bjid.2024.103740
    • Accession Number:
      38670168